Brokers Offer Predictions for ARTV Q1 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Wedbush issued their Q1 2026 earnings per share (EPS) estimates for Artiva Biotherapeutics in a research report issued to clients and investors on Thursday, May 8th. Wedbush analyst D. Nierengarten expects that the company will post earnings per share of ($0.73) for the quarter. Wedbush has a "Outperform" rating and a $18.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.95) per share. Wedbush also issued estimates for Artiva Biotherapeutics' Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.78) EPS and Q4 2026 earnings at ($0.81) EPS.

Several other research firms have also issued reports on ARTV. Needham & Company LLC lowered their target price on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday, March 26th. Finally, Cantor Fitzgerald dropped their price objective on Artiva Biotherapeutics from $23.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $19.40.

Artiva Biotherapeutics Stock Down 2.1%

ARTV stock traded down $0.05 during midday trading on Monday, hitting $2.09. 36,301 shares of the stock traded hands, compared to its average volume of 173,793. Artiva Biotherapeutics has a 1-year low of $1.78 and a 1-year high of $17.31. The stock's fifty day simple moving average is $2.95 and its 200-day simple moving average is $6.64.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.15).

Institutional Trading of Artiva Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. purchased a new position in Artiva Biotherapeutics in the 3rd quarter valued at about $7,435,000. Geode Capital Management LLC raised its holdings in shares of Artiva Biotherapeutics by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 315,758 shares of the company's stock valued at $3,184,000 after acquiring an additional 6,828 shares during the last quarter. Northern Trust Corp lifted its position in shares of Artiva Biotherapeutics by 3.8% in the fourth quarter. Northern Trust Corp now owns 117,112 shares of the company's stock valued at $1,180,000 after acquiring an additional 4,335 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Artiva Biotherapeutics by 26.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company's stock worth $165,000 after acquiring an additional 11,355 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Artiva Biotherapeutics in the first quarter worth approximately $144,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.